PASSAGE BIO, INC. Increase (Decrease) in Contract with Customer, Liability
PASSAGE BIO, INC. (PASG) reported Increase (Decrease) in Contract with Customer, Liability of $2.50 million for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-09-03
- PASSAGE BIO, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PASSAGE BIO, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $2.50M.
- PASSAGE BIO, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was $1.01M.
- PASSAGE BIO, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was $506.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.50M S-4/A · filed 2026-09-03 | |||
| 2025-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $2.50M derived: sum of 2 quarters · filed 2026-09-03 | $3.51M derived: sum of 3 quarters · filed 2026-09-03 | $4.01M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $2.50M derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-10 | $3.51M derived: sum of 2 quarters · filed 2026-09-03 | $4.01M 10-Q · filed 2025-11-10 | $7.24M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-06-30 | $1.01M derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | $1.51M S-4/A · filed 2026-09-03 | $4.74M derived: sum of 3 quarters · filed 2026-09-03 | |
| 2025-03-31 | $506.00K S-4 · filed 2026-07-21 | $3.73M derived: sum of 2 quarters · filed 2026-09-03 | ||
| 2024-12-31 | $3.23M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $8.23M S-4/A · filed 2026-09-03 | ||
| 2024-09-30 | $5.00M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |